Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WOBURN, MASS. , MAY 21, 2026 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) ("BIOFRONTERA" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), WILL PARTICIPATE IN A WEBCAST PRESENTATION AND HOST ONE-ON-ONE MEETINGS WITH INVESTORS AT THE LYTHAM PARTNERS SPRING 2026 INVESTOR CONFERENCE, TAKING PLACE VIRTUALLY ON THURSDAY, MAY 28, 2026.

BIOFRONTERA INC. TO PARTICIPATE IN THE LYTHAM PARTNERS SPRING 2026 INVESTOR CONFERENCE ON MAY 28, 2026

WOBURN, MA, MAY 14, 2026 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT) IN DERMATOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND PROVIDED A BUSINESS UPDATE.

BIOFRONTERA INC. REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

THE SECOND ANNUAL #HATSONFORAK CAMPAIGN RUNS MAY 1824, 2026, CULMINATING ON GLOBAL ACTINIC KERATOSIS (AK) AWARENESS DAY THIS SOCIAL MEDIADRIVEN INITIATIVE INVITES PEOPLE TO WEAR A HAT, SHARE A PHOTO, AND HELP RAISE AWARENESS OF AK AND THE IMPORTANCE OF COMPREHENSIVE SUN PROTECTION ACTINIC KERATOSIS AFFECTS AN ESTIMATED 58 MILLION AMERICANS AND, IF LEFT UNTREATED, CAN DEVELOP INTO SQUAMOUS CELL CARCINOMA1 WOBURN, MASS., MAY 13, 2026 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THE RETURN OF THE HATS ON CAMPAIGN FOR ITS SECOND CONSECUTIVE YEAR.

BIOFRONTERA LAUNCHES SECOND ANNUAL HATS ON CAMPAIGN TO RAISE AWARENESS OF ACTINIC KERATOSIS

WOBURN, MASS., MAY 08, 2026 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), ANNOUNCES IT WILL REPORT FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026 AFTER THE CLOSE OF THE U.S. FINANCIAL MARKETS ON THURSDAY, MAY 14, 2026. THE COMPANY WILL HOST A CONFERENCE CALL ON THURSDAY, MAY 14, 2026 AT 11:00 A.M. EASTERN TIME TO DISCUSS THOSE RESULTS, PROVIDE A BUSINESS UPDATE AND ANSWER QUESTIONS. CONFERENCE CALL AND WEBCAST INFORMATION

BIOFRONTERA INC. TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND HOST A CONFERENCE CALL ON MAY 14, 2026

CONFERENCE CALL WILL BE HELD TODAY, THURSDAY, MARCH 19 AT 10:00 AM ET WOBURN, MA, MARCH 19, 2026 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ:BFRI) (THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT) IN DERMATOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025 AND PROVIDED A BUSINESS UPDATE. FOURTH QUARTER FINANCIAL HIGHLIGHTS REVENUES FOR 4Q25 WERE A RECORD $17.1 MILLION, A 36% INCREASE COMPARED TO $12.6 MILLION FOR THE SAME PERIOD IN 2024.

BIOFRONTERA INC. REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

WOBURN, MASS., MARCH 09, 2026 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), ANNOUNCES IT WILL REPORT FINANCIAL RESULTS FOR THE THREE MONTHS AND FULL YEAR ENDED DECEMBER 31, 2025 AFTER THE CLOSE OF THE U.S. FINANCIAL MARKETS ON THURSDAY, MARCH 19, 2026. THE COMPANY WILL HOST A CONFERENCE CALL ON THURSDAY, MARCH 19, 2026 AT 10:00 A.M. EASTERN TIME TO DISCUSS THOSE RESULTS, PROVIDE A BUSINESS UPDATE AND ANSWER QUESTIONS.

BIOFRONTERA INC. TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND HOST A CONFERENCE CALL ON MARCH 19, 2026

 PHASE 2B STUDY DEMONSTRATED GREATER REDUCTIONS IN INFLAMMATORY ACNE LESIONS WITH AMELUZ  PDT VERSUS VEHICLE

BIOFRONTERA INC. REPORTS POSITIVE PHASE 2B RESULTS SUPPORTING FURTHER DEVELOPMENT OF AMELUZ PHOTODYNAMIC THERAPY FOR MODERATE TO SEVERE ACNE VULGARIS

WOBURN, MASS., FEB. 26, 2026 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE COMMERCIALIZATION AND DEVELOPMENT OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THAT ON FEBRUARY 23, 2026, THE U.S. PATENT TRIAL AND APPEAL BOARD (THE BOARD) ISSUED A FINAL WRITTEN DECISION FINDING ALL CHALLENGED CLAIMS OF SUN PHARMACEUTICAL INDUSTRIES, INC.'S U.S. PATENT NO. 11,697,028 (THE '028 PATENT) TO BE UNPATENTABLE.

U.S. PATENT OFFICE ISSUES FINAL WRITTEN DECISION FINDING ALL CHALLENGED CLAIMS OF SUN PHARMA'S PATENT 11,697,028 TO BE UNPATENTABLE

WOBURN, MASS., FEB. 17, 2026 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THAT THE DATABASE OF ITS PHASE 1 PK STUDY EVALUATING AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE) TOPICAL GEL FOR THE TREATMENT OF MILD TO MODERATE ACTINIC KERATOSES (AKS) ON NECK, TRUNK AND EXTREMITIES WAS LOCKED ON FEBRUARY 11, 2026.

BIOFRONTERA INC. ANNOUNCES DATABASE LOCK OF PHASE 1 PHARMACOKINETICS STUDY OF AMELUZ FOR ACTINIC KERATOSES ON TRUNK AND EXTREMITIES

WOBURN, MASS., FEB. 11, 2026 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE COMMERCIALIZATION AND DEVELOPMENT OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS COMPLETED ITS FILING REVIEW AND ACCEPTED FILING OF THE COMPANY'S SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE) TOPICAL GEL USED IN COMBINATION WITH THE RHODOLED RED-LIGHT LAMP SERIES FOR THE TREATMENT OF SBCC. THE FDA IDENTIFIED NO FILING DEFICIENCIES AND ASSIGNED A PDUFA TARGET ACTION DATE OF SEPTEMBER 28, 2026.

Biofrontera Inc.

BFRI

Price

Financial Reports

No items found.

Press Releases

Biofrontera Inc.

BFRI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BFRI